ReviewNature medicine2011
Diseases in a dish: modeling human genetic disorders using induced pluripotent cells.
Review in Nature medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)Autophagy · 2021Guideline
- Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced byScience advances · 2025Article
- Pros and Cons of Human Brain Organoids to Study Alzheimer's Disease.Aging and disease · 2024Review
- Germline PTEN genotype-dependent phenotypic divergence during the early neural developmental process of forebrain organoids.Molecular psychiatry · 2024Article
- Possible involvement of zinc transporter ZIP13 in myogenic differentiation.Scientific reports · 2024Article
- Mapping the global landscape for induced pluripotent stem cells from patents and clinical trials.Nature biotechnology · 2024Article
- The omics era: a nexus of untapped potential for Mendelian chromatinopathies.Human genetics · 2024Review
- Characterization of an iPSC-based barrier model for blood-brain barrier investigations using the SBAD0201 stem cell line.Fluids and barriers of the CNS · 2023Article
- Therapeutic function of a novel rat induced pluripotent stem cell line in a 6‑OHDA‑induced rat model of Parkinson's disease.International journal of molecular medicine · 2022Article
- Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson's Disease.Genes · 2022Review
- Cocktail Formula and Application Prospects for Oral and Maxillofacial Organoids.Tissue engineering and regenerative medicine · 2022Review
- Recapitulation of pro-inflammatory signature of monocytes with ACVR1A mutation using FOP patient-derived iPSCs.Orphanet journal of rare diseases · 2022Article
- Developmental modeling of hepatogenesis using obese iPSCs-hepatocyte differentiation uncovers pathological features.Cell death & disease · 2022Article
- Engineering the niche to differentiate and deploy cardiovascular cells.Current opinion in biotechnology · 2022Review
- High expression of uracil DNA glycosylase determines C to T substitution in human pluripotent stem cells.Molecular therapy. Nucleic acids · 2022Article
- Modeling and Targeting Neuroglial Interactions with Human Pluripotent Stem Cell Models.International journal of molecular sciences · 2022Review
- In Vitro Models of the Human Blood-Brain Barrier Utilising Human Induced Pluripotent Stem Cells: Opportunities and Challenges.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Review
- Formation of Osteochondral Organoids from Murine Induced Pluripotent Stem Cells.Tissue engineering. Part A · 2021Article
- AP-1 is a temporally regulated dual gatekeeper of reprogramming to pluripotency.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The derivation of induced pluripotent cells (iPSCs) from individuals suffering from genetic syndromes offers new opportunities for basic research into these diseases and the development of therapeutic compounds. iPSCs can self renew and can be differentiated to many cell types, offering a potentially unlimited source of material for study. In this review we discuss the conceptual and practical issues to consider when attempting to model genetic diseases using iPSCs.
Indexed as
Identifiers
22146428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.